Endpoint · otherGETclinicalintelpulse.theaslangroupllc.com /api/clinical/approval-outlook ?agency=FDA+%7C+EMA+%7C+both+%28default%3A+both%29&condition=Disease+area+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Multiple+Myeloma%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Obesity%22&horizon=12m+%7C+18m+%7C+24m+%28default%3A+18m%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29
FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results…
Read more
FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.Overview
Grade?
UNRATED
0 of 30 paid calls toward a letter
Price
$0.25 per call
Paid calls
none yet
delivery unknown until someone pays
More info
Seller?
URL
https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook?agency=FDA+%7C+EMA+%7C+both+%28default%3A+both%29&condition=Disease+area+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Multiple+Myeloma%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Obesity%22&horizon=12m+%7C+18m+%7C+24m+%28default%3A+18m%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29
Seen
first 2 months ago · last 4 days ago
113 free handshakes
Payment
Pays through
x402
Offered on?
algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k, Polygon, eip155:143, eip155:196, Arbitrum, eip155:480, eip155:56, Base USDC, eip155:999, Solana, xrpl:0
Listed on?
Polygon, Arbitrum, Base, Solana
Score, from free handshakes onlyweights 2026.09.6
UN
RATED
RATED
0.720 liveness verified, no letter
To a letter · 30 paid calls
0 of 30
Held down by latency p95 · gap to 1.000 is 0.280: 0.080 uncertain ? + 0.200 short ? · 0.080 to B
| Component | Weight | Measured | Lower bound ? | Adds | Short ? | Uncertain ? | |
|---|---|---|---|---|---|---|---|
| latency p95costs the most it answered as fast as its class |
0.20 | 0.00 | 0.000 | 0.000 | −0.200 | 0 | |
| liveness it answered at all |
0.60 | 1.00 | 0.866 | 0.520 | 0 | −0.080 | |
| price stability the price stayed where it was listed |
0.20 | 1.00 | 1.000 | 0.200 | 0 | 0 | |
| Composite | 1.00 | 0.720 | gap to 1.000 = 0.280 · 0.200 short · 0.080 uncertain | 0.720 | −0.200 | −0.080 |
Not measured: correctness · nobody paid; honesty · nobody paid; schema conformance · no answer had a published shape to check
The multiplication, written out
0.200 × 0.000 latency p95
+ 0.600 × 0.866 liveness
+ 0.200 × 1.000 price stability
= 0.720 → UNRATED: 46 of 30 paid calls weights 2026.09.6 · 46 samples · seed cap_01M1A51TG1WX3T5NM8FPDHBZEF|2026-10-14T12:54:04.931Z|2026.09.6
Verify it yourself
npx teppi-check https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook?agency=FDA+%7C+EMA+%7C+both+%28default%3A+both%29&condition=Disease+area+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Multiple+Myeloma%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Obesity%22&horizon=12m+%7C+18m+%7C+24m+%28default%3A+18m%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29curl -s https://api.teppi.xyz/v1/trust/cap_01M1A51TG1WX3T5NM8FPDHBZEF